Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2024-10-31 Capital/Financing Update
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the proposed issuance of debenture units and warrants by PharmaDrug Inc. It details the terms of the debentures, maturity, conversion price, and warrants, as well as background information about the company. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is an update on the company's financing activities, specifically about issuing debt instruments and related warrants. It is not an annual or interim report, audit report, or earnings release. It fits the category of Capital/Financing Update, as it provides information on fundraising and capital structure changes.
2024-10-31 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a stability study for a pharmaceutical product (PD-001) to support a Phase 1 clinical trial. It contains no financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any form of financial or regulatory filing. The content is primarily a corporate announcement about a scientific and clinical milestone. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate update, which corresponds to Regulatory Filings (RNS).
2024-10-31 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of clinical trial start-up activities for a pharmaceutical product (PD-001). It details the study design, objectives, and company background but does not contain any financial data, regulatory filings, or formal report content. It is an announcement of a clinical trial initiation rather than a financial or regulatory report. There is no indication of financial results, management changes, voting results, or other report types defined in the filing categories. Therefore, the document best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement or corporate update that does not fit other specific categories.
2024-09-19 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a scientific and clinical development update regarding PharmaDrug's subsidiary Sairiyo Therapeutics and their research on cepharanthine's potential to treat monkeypox (Mpox). It includes background information on the drug, clinical trial approvals, and forward-looking statements. There are no financial statements, regulatory filings, voting results, or management changes. The content is primarily a corporate announcement about research and development progress, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The document is best classified as a general corporate press release, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2024-08-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a Letter of Intent (LOI) between PharmaDrug's subsidiary SecureDose and a Canadian licensed dealer for the manufacturing and distribution of pharmaceutical grade cocaine. It discusses the company's strategic plans, patent filings, and forward-looking statements about the development and commercialization of a novel manufacturing process. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a corporate announcement about a business development and partnership intention rather than a formal financial report, regulatory filing, or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or business update that does not fit other specific categories, thus falling under Regulatory Filings (RNS).
2024-05-23 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a corporate update and forward-looking statement from PharmaDrug Inc., outlining strategic plans, development milestones, and commercialization efforts related to a patent-pending pharmaceutical-grade biosynthetic cocaine process. It is presented as a press release dated May 13, 2024, and includes no financial statements, detailed financial performance data, or regulatory filings. The content focuses on business strategy, market positioning, and future objectives rather than reporting actual financial results or regulatory compliance. It is not an earnings release, annual or interim report, audit report, or any other formal financial filing. The document is a corporate update or investor communication providing strategic and operational information. This fits best under the category of Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials, strategy, and market position, despite being in press release format. The length and detail support this classification rather than a brief announcement or regulatory filing.
2024-05-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.